Investments
The infrastructure of American life.
We invest in the enduring needs of a growing nation — housing, healthcare, energy, and the science of human health.
These are not trends. They are the permanent necessities of modern civilization.
Our Positions
Our portfolio exceeds $1 billion in assets across four core sectors.
Each position is backed by hard assets, institutional partnerships, and decades of operational expertise.
Real Estate
Institutional raises for premier development across key U.S. markets.
Healthcare
Nursing home and senior living — essential services, hard assets, and demand that outlasts cycles.
Energy
Infrastructure-grade investment built for long-term global demand.
Biotech
Precision capital at the intersection of science, innovation, and scale.
Multifamily Housing
878 units held outright, valued at over $220 million. A major interest in a 2,220-unit portfolio valued at $346 million. One of the larger privately held residential portfolios in the New York region.
Investment Thesis
Demand for quality multifamily housing in the New York metropolitan area has proven resilient across every economic cycle of the past half century. The reasons are structural and self-reinforcing: a constrained land supply, one of the most restrictive regulatory environments for new construction in the United States, a population that continues to grow, and an affordability gap between ownership and rental that keeps renters in the market longer than anywhere else in the country. We have built our residential portfolio on that conviction — and the market has rewarded patience consistently.
These are not financial instruments. They are assets embedded in the communities they serve.
Case Study: Selective Co-Investment in a High Barrier-to-Entry Portfolio
We evaluate multifamily opportunities continuously across the New York metropolitan area. Most do not meet our threshold. The criteria are demanding: location quality, asset condition, the defensibility of the rent base, and — critically — the degree to which new supply is structurally constrained. When all of those factors converge, we act.
One such opportunity presented itself in a portfolio of 2,220 well-located residential units across New York — assets positioned in submarkets where the combination of zoning restrictions, land scarcity, and construction costs makes meaningful new supply essentially impossible. The barriers to entry are not merely high. They are, in practical terms, permanent.
We acquired a major ownership interest in this portfolio, which carries a total value of $346 million. The investment thesis was straightforward: in a city where you cannot easily build, what already exists appreciates. Tenants stay. Income is stable. And the underlying asset grows in value not because of what we do, but because of what the market will not allow anyone else to do.
This is the kind of investment we seek — not the most visible, not the most complex, but the most certain.
Skilled Nursing & Senior Care
6 facilities. 1,200 licensed beds. $346 million in asset value. Minimal debt. Nearly 40 years of uninterrupted federal and state approval.
Investment Thesis
America is aging. By 2050, the population over 65 will nearly double. The demand for skilled nursing and long-term care is not a projection — it is a demographic certainty written into the structure of the country.
Since 1987, we have owned and operated skilled nursing and senior care facilities across New York State. Our 6 properties encompass 1,200 licensed beds and carry a combined asset value of $346 million — held with minimal to zero debt, representing one of the strongest equity positions in our portfolio.
Operating these facilities requires continuous authorization from federal and state regulators, including the United States Department of Health and Human Services and the New York State Department of Health. We have maintained that authorization without interruption for nearly four decades. That record is not administrative. It is a testimony to the standard of care we deliver, and to the trust that government bodies — at every level — have placed in this organization.
These assets do not merely hold their value. They serve a need that American society cannot defer, cannot outsource, and cannot outgrow.
Energy Trading
Case Study: Recognizing opportunity where institutional conviction meets essential infrastructure.
A $40 million investment alongside one of the world's most respected institutional asset managers.
When we identified an energy trading platform with a differentiated market position and structural tailwinds unique to the electricity sector, we moved with conviction. We have invested over $40 million in this platform — and our judgment has since been validated by one of the most demanding institutional investors in the world.
Millennium Management — one of the largest and most sophisticated investment firms globally, with $86.7 billion in assets under management and a 35-year track record — has become our partner in this investment. Millennium does not co-invest casually. Their participation is an independent confirmation of the platform's quality and the opportunity's scale.
Investment Thesis
Electricity is not discretionary. The grid that delivers it, and the institutions that trade and manage its flow, occupy a position of permanent structural importance in the American economy. Our position in this sector reflects the same conviction that has guided every investment we have made: that the infrastructure powering American life is among the most durable and defensible assets available.
Co-investing alongside Millennium is not merely a financial arrangement. It is a statement about the caliber of partners this family attracts — and the institutional-grade standards to which we hold every position we take.
Biotechnology
Case Study: Patient capital, pioneering science, and the conviction to invest before the world was watching.
$250 million invested in a company now valued at $3 billion.
Not every essential investment is made of steel and concrete. The future of human health — how disease is diagnosed, treated, and ultimately defeated — is being written in laboratories. Years ago, we identified a leading researcher at the frontier of drug development and made a decision that few family enterprises would have the conviction or the patience to make.
That investment, placed before the company's potential was widely recognized, is today valued at $250 million within a company whose total value has reached $3 billion. It is among the most significant returns in our portfolio's history — and it was built not on speculation, but on a careful assessment of the science, the team, and the permanence of the problem being solved.
This is what vision looks like when it is backed by discipline.
For more than 75 years, this family has earned the trust of communities, residents, patients, and the United States government. We own and operate the infrastructure Americans depend upon — and we take that responsibility as seriously as any obligation we carry.
Every asset in this portfolio was chosen for the same reason: because it will still matter in twenty years. That is the only criterion that has ever guided us.